Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important drug class for treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and GI nurses will encounter more patients on these oral small-molecule agents in both infusion suites and outpatient GI clinics.
• Understanding that JAK3 signaling mediates common gamma chain cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) helps nurses explain to patients why these medications broadly dampen immune activity—and why infection risk, vaccination status, and screening for latent infections (e.g., TB, hepatitis B) are essential before and during therapy.
• Because JAK inhibitors carry black-box warnings for thrombosis, malignancy, and major adverse cardiovascular events, GI nurses play a key role in pre-treatment risk assessment, patient education, and ongoing symptom monitoring during clinic visits and follow-up calls.
• This foundational research underscores the biologic rationale behind an entire pipeline of JAK-targeted therapies now used across autoimmune conditions relevant to GI patients, including IBD, psoriatic arthritis, and ankylosing spondylitis—conditions nurses frequently see in patients with overlapping rheumatologic and GI comorbidities.

Clinical Relevance

This research summary describes the discovery of Jak3 and its role in cytokine signaling—foundational science that underlies the development of JAK inhibitors now used in GI practice, such as tofacitinib and upadacitinib for ulcerative colitis. For endoscopy and GI nurses, this translates into practical, day-to-day considerations: patients on JAK inhibitors require careful pre-procedure medication review, as these drugs affect immune competence and wound healing, and holding parameters around endoscopic procedures (particularly those involving biopsy, polypectomy, or therapeutic intervention) should be clarified with the gastroenterologist.

Nurses coordinating care for IBD patients on JAK inhibitor therapy should be prepared to discuss with patients the mechanism of action in accessible terms—these medications block intracellular signaling pathways activated by cytokines, thereby reducing the inflammatory cascade responsible for GI mucosal damage. This is distinct from biologic therapies (e.g., anti-TNF or anti-integrin agents) that patients may already be familiar with, so patient education materials and teaching sessions should differentiate oral small-molecule JAK inhibitors from injectable/infused biologics, including differences in onset of action, monitoring requirements (CBC, lipid panel, liver function), and dosing schedules.

From an operational standpoint, units treating IBD patients should ensure staff are trained to recognize signs of JAK inhibitor-related adverse events—including herpes zoster reactivation, venous thromboembolism, and unusual infections—since patients may present to endoscopy or infusion units with symptoms requiring triage and physician notification. Staying current on this rapidly evolving drug class also supports nurses' professional development, as JAK inhibitors continue to expand into new indications and combination regimens within gastroenterology.

Bottom Line

JAK inhibitors, rooted in foundational cytokine-signaling research like the discovery of Jak3, are an expanding therapeutic option for IBD and related autoimmune conditions—GI nurses should be well-versed in their mechanism, safety monitoring requirements, and pre-procedure considerations to provide safe, informed care for this growing patient population.